| Net Revenues |
(22)Net Revenues Net revenues are mainly generated from the sale of goods. The distribution of net consolidated revenues for 2025, 2024 and 2023 by segment is as follows: | | | | | | | | | Millions of Euros | | | 2025 | | 2024 | | 2023 | Biopharma | | 6,487 | | 6,143 | | 5,558 | Diagnostic | | 640 | | 645 | | 670 | Bio supplies | | 154 | | 216 | | 160 | Others | | 243 | | 208 | | 204 | Net sales | | 7,524 | | 7,212 | | 6,592 |
The geographical distribution of net consolidated revenues is as follows: | | | | | | | | | Millions of Euros | | | 2025 | | 2024 | | 2023 | USA and Canada | | 4,253 | | 4,087 | | 3,899 | Spain | | 418 | | 423 | | 363 | European Union | | 1,196 | | 1,076 | | 893 | Rest of the world | | 1,657 | | 1,626 | | 1,437 | Net sales | | 7,524 | | 7,212 | | 6,592 |
Details of discounts and other reductions in gross revenue are as follows: | | | | | | | | | Millions of Euros | | | 2025 | | 2024 | | 2023 | Gross sales | | 10,603 | | 9,490 | | 8,389 | Chargebacks | | (2,524) | | (1,892) | | (1,525) | Cash discounts | | (115) | | (93) | | (82) | Volume rebates | | (60) | | (76) | | (59) | Medicare and Medicaid | | (182) | | (72) | | (68) | Other discounts | | (197) | | (144) | | (63) | Net sales | | 7,524 | | 7,212 | | 6,592 |
Movement in discounts and other reductions in gross revenue during 2025 is as follows: | | | | | | | | | | | | | | | Millions of Euros | | | | | | | | | Medicare / | | Other | | | | | Chargebacks | | Cash discounts | | Volume rebates | | Medicaid | | discounts | | Total | Balance at 31 December 2024 | | 386 | | 7 | | 41 | | 25 | | 102 | | 561 | Current estimate related to sales made in current and previous periods (1) | | 2,524 | | 115 | | 60 | | 182 | | 197 | | 3,078 | (Actual returns or credits in current period related to sales made in current and previous periods) (2) | | (2,391) | | (106) | | (73) | | (133) | | (178) | | (2,881) | Translation differences | | (51) | | (5) | | (6) | | (5) | | (2) | | (69) | Balance at 31 December 2025 | | 468 | | 11 | | 22 | | 69 | | 119 | | 689 |
| (1) | Net impact in the Consolidated Statements of Profit and Loss: estimate for the current year plus prior years’ adjustments. Adjustments made during the year corresponding to prior years’ estimates have not been significant. |
| (2) | Amounts credited and posted against provisions for current and previous periods. |
Movement in discounts and other reductions to gross revenue during 2024 was as follows: | | | | | | | | | | | | | | | Millions of Euros | | | | | | | | | Medicare / | | Other | | | | | Chargebacks | | Cash discounts | | Volume rebates | | Medicaid | | discounts | | Total | Balance at 31 December 2023 | | 318 | | 7 | | 24 | | 26 | | 35 | | 410 | Current estimate related to sales made in current and previous periods (1) | | 1,892 | | 93 | | 76 | | 72 | | 144 | | 2,277 | (Actual returns or credits in current period related to sales made in current and previous periods) (2) | | (1,842) | | (92) | | (61) | | (75) | | (77) | | (2,147) | Translation differences | | 18 | | (1) | | 2 | | 2 | | — | | 21 | Balance at 31 December 2024 | | 386 | | 7 | | 41 | | 25 | | 102 | | 561 |
Movement in discounts and other reductions to gross revenue during 2023 was as follows: | | | | | | | | | | | | | | | Millions of Euros | | | | | | | | | Medicare / | | Other | | | | | Chargebacks | | Cash discounts | | Volume rebates | | Medicaid | | discounts | | Total | Balance at 31 December 2022 | | 264 | | 6 | | 24 | | 27 | | 26 | | 347 | Current estimate related to sales made in current and previous periods (1) | | 1,525 | | 82 | | 59 | | 68 | | 63 | | 1,797 | (Actual returns or credits in current period related to sales made in current and previous periods) (2) | | (1,460) | | (81) | | (58) | | (68) | | (54) | | (1,721) | Translation differences | | (11) | | — | | (1) | | (1) | | — | | (13) | Balance at 31 December 2023 | | 318 | | 7 | | 24 | | 26 | | 35 | | 410 |
|